Cabazitaxel-d6

Cabazitaxel-d6 is the deuterium labeled Cabazitaxel. Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity[1][2].

Product Specifications

CAS Number

[1383561-29-2]

Product Name Alternative

XRP6258-d6; RPR-116258A-d6; taxoid XRP6258-d6

UNSPSC

12352005

Hazard Statement

H302, H315, H341, H361, H373

Target

Autophagy; Microtubule/Tubulin

Type

Isotope-Labeled Compounds

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Cytoskeleton

Field of Research

Cancer

Purity

97.90

Solubility

10 mM in DMSO|DMSO : ≥ 100mg/mL

Smiles

CC(O[C@]([C@@]1([H])C[C@@H]2OC([2H])([2H])[2H])(CO1)[C@@]([C@@]2(C([C@@H]3OC([2H])([2H])[2H])=O)C)([H])[C@@H]([C@@](C(C)(C3=C4C)C)(C[C@@H]4OC([C@H](O)[C@H](C5=CC=CC=C5)NC(OC(C)(C)C)=O)=O)O)OC(C6=CC=CC=C6)=O)=O

Molecular Formula

C45H51D6NO14

Molecular Weight

841.97

Precautions

H302, H315, H341, H361, H373

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond) . 2017 Sep;12 (17) :2083-2095.|[3]Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29.